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Objectives. This study examined the direct effects of pravastatin
on the artery wall of atherosclerotic monkeys after dietary lipid
lowering.
Background. Clinical trials suggest that hepatic hydroxymeth-
ylglutaryl coenzyme A reductase inhibitors may reduce the risk of
coronary heart disease out of proportion to their effect on
angiographically assessed lumen stenosis.
Methods. Thirty-two cynomolgus monkeys were fed an athero-
genic diet for 2 years (progression phase) and then fed a lipid-
lowering diet either containing (n 5 14) or not containing (n 5
18) pravastatin in the diet for an additional 2 years (treatment
phase). As designed, total plasma cholesterol and high density
lipoprotein concentrations did not differ between groups at the
beginning of or during the treatment phase of the experiment (p >
0.05).
Results. Quantitative angiography revealed that coronary ar-
teries of the pravastatin-treated monkeys dilated 10 6 3%,
whereas those from untreated control monkeys constricted 22 6
2% in response to acetylcholine (p < 0.05). There were no
treatment effects on plaque size of coronary arteries measured at
the end of the treatment phase of the study (0.110 6 0.048 mm2
[untreated] vs. 0.125 6 0.051 mm2 [pravastatin]; p > 0.05) or on
the amount of reduction in plaque size in common iliac arteries
during the treatment phase of the study (48 6 5% [untreated] vs.
45 6 6% [pravastatin]; p > 0.05). However, histochemical anal-
ysis of the atherosclerotic lesions indicated that the arteries from
pravastatin-treated monkeys had significantly fewer macrophages
in the intima and media, less calcification and less neovascular-
ization in the intima (p < 0.05).
Conclusions. We conclude that compared with control monkeys,
the arteries of pravastatin-treated monkeys had better dilator
function and plaque characteristics more consistent with plaque
stability than those of monkeys not receiving pravastatin. These
beneficial arterial effects of pravastatin occurred independently
of plasma lipoprotein concentrations and despite similar changes
in plaque size between the groups.
(J Am Coll Cardiol 1998;31:684–91)
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The traditional strategy for measuring the extent, severity and
progression or regression of coronary artery atherosclerosis
has been angiographic analysis of lumen narrowing or histo-
morphometric analysis of plaque size. However, serial angio-
graphic studies indicate that acute ischemic syndromes often
arise from thrombotic occlusion at sites that previously had
only mild or insignificant narrowing (1–4). Furthermore, lipid-
lowering studies have shown large reductions in clinical events
despite only modest improvement in coronary stenoses (5–8).
In monkeys, lipid-lowering studies have shown improved vaso-
dilator function despite modest reductions in plaque size (9).
These findings suggest that changes in plaque size or lumen
encroachment alone do not predict coronary events.
Coronary artery vasomotor function and plaque lesion
characteristics (e.g., cell type, necrosis, neovascularization,
fibrous cap thickness) may be important mediators of acute
coronary events (10–17). Improvements in these variables may
account for the reduced incidence of coronary events (18).
Atherosclerosis impairs dilator responses (19,20) and aug-
ments constrictor responses (21,22) of large epicardial and
smaller, resistance-size coronary arteries. Lowering of plasma
cholesterol concentrations by dietary means improves dilator
responses and lessens constrictor responses of coronary arter-
ies (9,21–24). These improvements may lessen the chance of
inappropriate coronary artery constriction, vasospasm and
possible plaque disruption.
In addition, certain plaque characteristics are thought to
increase the likelihood of plaque rupture, intraplaque hemor-
rhage and mural thrombosis. Areas of plaque rupture charac-
teristically contain large numbers of intimal macrophages in
association with plaque necrosis, calcification and neovascular-
ization (15–19). Plaques that have ruptured also have a thin
fibrous cap (13,14). Thus, it seems likely that a treatment
regimen that reduces characteristics of lesion vulnerability may
serve to stabilize plaque and reduce coronary events.
Pravastatin is a hydroxymethylglutaryl coenzyme A (HMG-
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CoA) reductase inhibitor that lowers plasma cholesterol con-
centrations in humans by 30% to 40% (25,26). This decrease in
plasma cholesterol concentrations correlates with a reduction
in coronary events (27). However, recent evidence indicates
that HMG-CoA reductase inhibitors have beneficial effects on
the incidence of transient myocardial ischemia (28),
endothelium-mediated dilation (29–31) and smooth muscle
cell proliferation (32). We designed a study to determine the
effects of pravastatin on vasomotor function and plaque char-
acteristics independent of any lipid-lowering effects.
Methods
Design. Experimental subjects included 32 adult (7 to 10
years of age) male cynomolgus monkeys (Macaca fascicularis)
imported directly from Indonesia. They consumed an athero-
genic diet containing 0.61 mg of cholesterol per kilocalorie of
diet for 2 years (progression phase). The monkeys were divided
into two groups so that groups had similar intimal areas in their
iliac arteries (see later discussion) and similar total plasma
cholesterol (TPC) and high density lipoprotein (HDL) choles-
terol concentrations at the beginning of the treatment phase.
Both groups then consumed a lipid-lowering diet containing
0.11 mg of cholesterol per kilocalorie of diet for an additional
2 years. The diets were adjusted slightly throughout the
treatment phase to maintain equal changes in plasma lipopro-
teins. The monkeys’ lipid-lowering diets contained (n 5 14) or
did not contain (n 5 18) pravastatin (20 mg/kg body weight per
day). One iliac artery was surgically removed at the beginning
of the treatment phase to serve as a baseline measure of plaque
regression (see later details). Vascular reactivity was measured
by coronary angiography at the end of the regression phase of
the experiment, just before death and necropsy (see later
details). Arterial tissue was removed and preserved in different
manners for optimal determination of various plaque charac-
teristics (see later details). All experimental procedures were
done in compliance with the Guide for the Care and Use of
Laboratory Animals, and were approved by the Institutional
Animal Care and Use Committee of the Bowman Gray School
of Medicine.
Lipid and lipoprotein measurements. Venous blood sam-
ples were obtained from monkeys sedated with ketamine
hydrochloride (10 to 15 mg/kg intramuscularly) during the
progression phase of the experiment and at 3-month intervals
during the regression phase of the experiment. All samples
were collected from monkeys that had fasted overnight. Total
plasma cholesterol was measured by the methods of Allain et
al. (33) and HDL cholesterol by the methods described in the
Manual of Laboratory Operations of the Lipid Research Clinics
Program (34). Low density lipoprotein (LDL) cholesterol
concentrations were determined indirectly by subtracting HDL
cholesterol from TPC. Therefore, the term “LDL cholesterol”
is used throughout this report, but actually represents LDL
cholesterol plus very low density lipoprotein (VLDL) choles-
terol. The details of the methods used to measure these
components have been published previously (35).
Coronary artery reactivity. Vascular responses of large
epicardial coronary arteries were measured just before death
and necropsy. The monkeys were anesthetized with ketamine
hydrochloride (15 mg/kg intramuscularly) and butorphanol
(0.025 mg/kg intramuscularly). Supplemental doses of both
agents were given as required to maintain light anesthesia. The
animals were allowed to breathe spontaneously. These anes-
thetic agents were chosen because they do not interfere
significantly with blood pressure, heart rate or respiration rate.
The monkeys were warmed with a heating pad. A custom-
designed 3F (tapered to 1.5F) catheter was inserted into the
right femoral artery and advanced into the left main coronary
artery under fluoroscopic guidance.
With an infusion pump (Harvard Apparatus), serial 2-min
infusions were made in the following sequence: 1) 5% dextrose
in water (control); 2) acetylcholine (1028, 1027 and 1026
mol/liter) (estimated final concentration in the coronary ar-
tery); 3) another control; and 4) nitroglycerin (15 mg/min).
Images were taken during hand injection of 2 ml of nonionic
contrast solution (Omnipaque, Squibb) into the left main
coronary artery.
Quantitative coronary angiography (QCA) was done in the
Wake Forest University Cardiology Image Analysis Labora-
tory. A single frame from baseline and after each infusion was
selected for analysis on the basis of clarity of the image of the
proximal 2 to 3 cm of the circumflex coronary artery. Criteria
for clarity included maximal opacification, no overlapping
structures and minimal motion artifact. In addition, images
were considered acceptable only if the heart rate (monitored
by electrocardiography) did not vary from baseline by .20%
during infusion of agonists. Care was taken to select all frames
from a single monkey at the same time in the cardiac cycle
(end-diastole). Each frame was optimally magnified by use of a
cine video projector (SME-3500, Sony Corporation of Amer-
ica) and digitized to a 480 3 384 3 10-bit gray-scale image by
use of a frame grabber (4 megabytes, Epix Inc.) installed in a
486 personal computer. The mean diameters of the vessel
segments of interest were measured by previously validated
QCA methods (QCA Plus, Sanders Data Systems) (9). When
possible, specific anatomic landmarks were used to ensure that
the same portion of the vessel was analyzed after each infusion.
Each film was analyzed identically on two separate occasions
by an operator who was unaware of the initial results. For
purposes of analysis, the average of the two measurements at
Abbreviations and Acronyms
ANOVA 5 analysis of variance
HDL 5 high density lipoprotein
HMG-CoA 5 hydroxymethylglutaryl coenzyme A
LDL 5 low density lipoprotein
QCA 5 quantitative coronary angiography
TPC 5 total plasma cholesterol
VLDL 5 very low density lipoprotein
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baseline and after each infusion were used. Estimates of the
precision and reproducibility of the QCA methods, as applied
to monkeys, have been published previously (9).
Evaluations of atherosclerotic plaque size in coronary
arteries. Necropsies were done on the monkeys at the end of
the treatment phase of the study. Monkeys were sedated with
ketamine hydrochloride (15 mg/kg intramuscularly) for trans-
port to the necropsy laboratory. At necropsy, sodium pento-
barbital (13 mg/kg intravenously) was administered to attain
surgical anesthesia. An infusion of Ringer’s solution was
initiated through an 18-gauge needle inserted into the left
ventricle. Death was effected with an intravenous injection of
sodium pentobarbital (80 mg/kg). A 1-cm longitudinal incision
was made in the abdominal aorta for drainage of blood from
the cardiovascular system. When the drainage from the vena
cava became clear, the heart was rapidly removed and the
coronary arteries perfusion-fixed with 10% neutral buffered
formalin for 1 h.
A total of 15 standardized blocks of coronary artery (five
each from the left circumflex, left anterior descending and
right coronary arteries) were cut perpendicular to the long axis
of the arteries. The tissue blocks were dehydrated through
increasing concentrations of ethanol and embedded in paraffin.
Two 5-mm sections were cut from each block and stained with
either hematoxylin-eosin or Verhoeff-van Gieson. Sections of
arteries stained with Verhoeff-van Gieson were projected,
using a microscope, onto a digitizer plate. Using a hand-held
stylus and a computer-assisted digitizer, the component parts
of the artery were traced. Intimal areas were determined by
digitizing the area between the internal elastic lamina and the
lumen surface of each artery section. The integration method
was used to calculate intimal area. Lumen area was calculated
by subtracting the intimal area from the area inside the
internal elastic lamina.
Evaluation of plaque size in the common iliac arteries.
Immediately before the treatment phase of the study, either a
left or right common iliac artery was surgically removed from
each monkey. Monkeys were tranquilized with ketamine hy-
drochloride (15 mg/kg intramuscularly) and then given
30 mg/kg of sodium pentobarbital intravenously to attain
surgical anesthesia. The monkeys were intubated and placed
on mechanical ventilation. The common iliac artery was re-
moved through a midline abdominal incision. The artery was
immediately cannulated and perfusion-fixed with 10% neutral
buffered formalin at 100 mm Hg for 1 h. The contralateral
common iliac artery was perfusion-fixed similarly in situ after
removal of the heart. To study the extent and severity of iliac
artery atherosclerosis, three standard blocks (each 3 mm long
and representing the proximal, middle and distal portions of
both arteries) were cut perpendicular to the long axis of the
arteries. Histologic preparation and staining were the same as
noted earlier. Intimal areas of the iliac artery removed before
treatment were used to determine the change in intimal area,
as measured at the end of the experiment. Extent of athero-
sclerosis in the iliac artery removed at baseline was used as a
randomization variable to divide animals into treatment groups.
Evaluation of lesion characteristics in the carotid artery.
Right common carotid arteries were collected from the mon-
keys at necropsy, embedded in OCT and snap-frozen in
isopentane cooled in liquid nitrogen. Two sections of artery
(each 5 mm long) were cut from the proximal common carotid
artery. These sections were used to evaluate: 1) cell type—cell-
specific antibodies: HHF35 anti-muscle actin for vascular
smooth muscle cells (Enzo Diagnostics); CD68 (clone KP1)
anti-human macrophage; 2) calcification—by hematoxylin-
eosin stain; 3) neovascularization—CD31 anti-human endo-
thelial cells, by hematoxylin background stain; and 4) necro-
sis—by hematoxylin-eosin stain. Serial sections were cut from
each block and used for the hematoxylin-eosin staining and
macrophage (smooth muscle) and endothelial cell determina-
tions. Each tissue section was examined independently by two
observers (G.K.S. and J.K.W.). Forty observations were made
for each end point in each of the two groups. Data are presented
as percent shift in frequency distribution of those observations
between groups. The lesion characteristics were assigned numer-
ical grades (1, 2 or 3) based on cell composition (macrophages
and smooth muscle cells) and features of plaque complication
such as calcification, necrosis or neovascularization.
Grade 1 lesions. In mild to uninvolved lesion sections, there
was no plaque present (save for a minimal amount of fatty
streak), few to no macrophages, no necrosis or calcification
and only adventitial vasa vasorum (Fig. 1, top).
Grade 2 lesions. In the moderately involved lesion sections,
we generally observed mild to moderate intimal thickening,
occasional nests of macrophages and lipid-laden smooth mus-
cle cells in the intima, little to no necrosis and calcification and
moderate adventitial neovascularization (Fig. 1, middle).
Grade 3 lesions. In the more advanced atheromas, there
tended to be moderate to advanced atherosclerotic plaque
development with numerous nests of macrophage and smooth
muscle cells within the intima. Plaque necrosis and calcification
were common, as well as neovascularization that extended well
into the intima. Plaque necrosis was frequently associated with
a thin fibrous cap (Fig. 1, bottom).
Statistics. Potential treatment effects on plasma lipopro-
tein concentrations were analyzed using repeated-measures
analysis of variance (ANOVA). Potential treatment effects on
extent of coronary artery atherosclerosis were analyzed using
ANOVA. Potential treatment effects on plaque size reduction
in the iliac arteries were analyzed using repeated-measures
ANOVA. Potential treatment effects on frequency distribu-
tions of plaque characteristics were analyzed using the Mann-
Whitney U test. Statistical significance was assigned at the 95%
confidence level.
Results
Coronary heart disease risk factor measurements (plasma
lipoproteins). Concentrations of TPC and LDL and HDL
cholesterol were similar between groups at the beginning of
the regression phase of the experiment. During the regression
phase, there were similar decreases across time in TPC and
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LDL and HDL cholesterol (Fig. 2) (p . 0.05 for all intergroup
comparisons).
Vascular reactivity. There was an overall treatment effect
of pravastatin on vascular response to acetylcholine (p , 0.05).
There were no effects of treatment on dilator responses to
nitroglycerin (p . 0.05 for all intergroup comparisons) (Fig. 3).
Atherosclerosis extent. Plaque size and lumen size mea-
surements (intimal area) in the coronary arteries were similar
between groups at the end of the lipid-lowering phase of the
experiment (p . 0.05) (Table 1). There were similar reductions
in plaque size of the common iliac arteries during the regres-
sion phase of the experiment in both groups (p . 0.05) (Table
1).
Plaque characteristics. Histologic grading of arteries indi-
cated that there was a shift in frequency distribution from
plaques with more macrophages in the intima and media to
plaques with few macrophages in these areas when monkeys
were treated with pravastatin (p , 0.05 vs. control) (Fig. 4). A
similar shift in frequency distribution was seen when evaluating
the extent of intima-media neovascularization (p , 0.05) (Fig.
5) and intimal calcification (p , 0.05) (Fig. 6).
Discussion
The major finding of this study was that pravastatin plus an
aggressive lipid-lowering diet did not result in additional
improvements in plasma lipids or coronary and iliac intimal
area beyond what was achieved by the lipid-lowering diet
alone. However, the addition of pravastatin was associated
with improvements in endothelial function and a shift toward
lesion characteristics associated with more plaque stability.
Plasma lipoproteins. Treatment of people with pravastatin
and other HMG-CoA reductase inhibitors consistently reduces
TPC and LDL cholesterol concentrations by 20% to 40% and
increases HDL cholesterol concentrations by ;10% (26,28).
These improvements in plasma lipoprotein concentrations
have been associated with substantial reductions in coronary
events (28). Results recently reported by the Regression
Growth Evaluation Statin Study (REGRESS) group (28)
indicate that addition of HMG-CoA reductase inhibitors to the
conventional treatment of patients with angina pectoris re-
duces episodes of transient myocardial ischemia gauged by
ambulatory ST segment monitoring. Furthermore, the effect of
Figure 1. Representative histologic
cross sections illustrating atherosclerotic
lesion grades from blocks of carotid
arteries of male cynomolgus monkeys:
grade 1 (top); grade 2 (middle); grade 3
(bottom). SMC 5 smooth muscle cells.
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pravastatin remained significant after adjustment for indepen-
dent risk factors for the occurrence of ischemia. Treatment
with lovastatin (31) or pravastatin (29) improves endothelium-
mediated responses in patients with atherosclerosis. Collec-
tively, these studies indicate that HMG-CoA reductase inhib-
itors have direct effects on the artery wall that may contribute
to reducing coronary events.
These studies are intriguing, but it is difficult to determine
if the observed results (e.g., on vascular reactivity) result from
pravastatin’s plasma lipid-lowering properties or some
lipoprotein-independent effects on the artery wall, or both.
Thus, the current study isolated the plasma lipid effects of
pravastatin by producing equal TPC lowering and HDL cho-
lesterol raising in both pravastatin-treated monkeys and un-
treated control monkeys. This was done by feeding a plasma
cholesterol-lowering diet to both groups of monkeys, while
treating one group with pravastatin. As expected, there were
similar reductions in TPC and increases in HDL cholesterol in
both groups of animals throughout the regression phase of the
experiment. Thus, it can be assumed that the arteries, liver and
other cholesterol-sensitive tissues were exposed to similar
amounts of cholesterol. We conclude that any observed effects of
Figure 2. Total plasma cholesterol (TPC), LDL cholesterol (LDL-C)
and HDL cholesterol (HDL-C) concentrations in male cynomolgus
monkeys during the treatment phase of the experiment. As designed in
the experimental protocol, diets were adjusted so that there was
equivalent TPC and LDL cholesterol decreases and HDL cholesterol
increases during the treatment phase of the experiment.
Figure 3. Effect of pravastatin on coronary artery diameter changes in
response to acetylcholine (ACH) in male cynomolgus monkeys at
1028, 1027 and 1026 mol/liter (estimated final concentration in coro-
nary artery) and nitroglycerin (NTG) (15 mg/min). C1 5 first control
infusion; C2 5 second control infusion (5% dextrose in water). *p ,
0.05 versus control group. Error bars indicate mean value 6 SEM.
Table 1. Effects of Pravastatin on Coronary and Iliac Artery
Atherosclerosis in Male Cynomolgus Monkeys
Control Group
(n 5 18)
Pravastatin Group
(n 5 14)
Coronary arteries
Intimal area (mm2)
Unadjusted 0.469 6 0.168 0.389 6 0.139
Adjusted* 0.460 6 0.061 0.401 6 0.069
Maximal intimal thickness (mm)
Unadjusted 0.152 6 0.037 0.119 6 0.029
Adjusted* 0.150 6 0.017 0.121 6 0.019
Lumen area (mm2)
Unadjusted 1.254 6 0.130 1.456 6 0.251
Adjusted* 1.246 6 0.118 1.467 6 0.134
Iliac arteries
Intimal area (mm2)
Baseline 1.155 6 0.542 1.088 6 0.341
Outcome 0.832 6 0.321 0.954 6 0.379
Change from baseline 20.323 6 0.240 20.133 6 0.151
*Mean values are adjusted for baseline atherosclerotic extent in the iliac
artery biopsy. Data are presented as mean values 6 SEM.
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pravastatin on measured experimental end points did not depend
on its plasma lipoprotein-lowering properties.
Vascular reactivity. Dietary lowering of plasma cholesterol
concentrations improves impaired endothelium-mediated dila-
tion of coronary arteries among nonhuman primates (36). Two
studies show that treatment with pravastatin improves or
preserves endothelium-mediated dilation of arteries in patients
with hypercholesterolemia and atherosclerosis (29,30). Results
of the study by Kamata et al. (30) indicate that pravastatin
preserves endothelium-mediated, nitric oxide–dependent dila-
tion of arteries in cholesterol-fed mice. The investigators
speculated that pravastatin’s effects on LDL oxidation may
serve as a mechanism by which this agent preserves nitric
oxide–mediated dilation. Results of our study indicate that
pravastatin may have effects on acetylcholine-mediated dila-
tion independent of its effects on plasma lipoproteins. We
interpret this to indicate that there is a favorable effect of
pravastatin directly at the level of the arterial wall affecting
endothelial function, because we saw a beneficial effect of
pravastatin on acetylcholine-mediated dilation (an index of
nitric oxide release by the endothelium that has direct
effects on smooth muscle cells), but not on nitroglycerin-
mediated dilation (an index of smooth muscle cell respon-
siveness). We speculate, therefore, that pravastatin has
direct effects on functional aspects of the artery wall (pos-
sibly the endothelium) that may explain, in part, its favor-
able effects on coronary events. However, the precise mech-
anism for the non-lipid-mediated effect on endothelial
function remains unknown.
Plaque extent. Our results do not support an additional
lipid-independent effect of pravastatin on reductions in plaque
size. These results are not entirely unexpected. Treatment with
HMG-CoA reductase inhibitors has been shown to reduce
coronary events despite modest reductions in preexisting high
grade stenoses (25,26). Cholesterol lowering with dietary ma-
nipulation results in modest reductions in coronary artery
plaque size in monkeys (9,36) and inhibition of atherosclerotic
progression in humans (37,38). However, the degree of plaque
“shrinkage” greatly depends on the amount of cholesterol
lowering produced. When plasma cholesterol concentrations
in monkeys are reduced from 600 to 100 mg/dl, there is a
reduction of ;50% in plaque size, mostly due to removal of
foam cells (39). When TPC concentrations are lowered from
350 to 150 mg/dl, there is little reduction in plaque size (9,36).
The second scenario is more consistent with the amount of
cholesterol lowering produced in humans by dietary manipu-
lations or drug treatment. Thus, it is unlikely that a reduction in
plaque size per se is the major mechanism by which cholesterol
lowering reduces the incidence of coronary events (40).
Figure 4. Frequency distribution of macrophages (shown as percent
change from control group) evaluated in the adventitia, media and
intima of coronary arteries of male cynomolgus monkeys. Bars above
zero indicate an increase in the number of arteries evaluated that fell
within that lesion grade; bars below zero indicate a decrease in the
number of arteries evaluated that fell within that lesion grade. *p ,
0.05 versus control group.
Figure 5. Frequency distribution of neovascularization (arterial vasa)
(shown as percent change from control group) evaluated in the
adventitia, media and intima of coronary arteries of male cynomolgus
monkeys. Bars above zero indicate an increase in the number of
arteries evaluated that fell within that lesion grade; bars below zero
indicate a decrease in the number of arteries evaluated that fell within
that lesion grade. *p , 0.05 versus control group.
Figure 6. Frequency distribution of plaque calcification (shown as
percent change from control group) evaluated in the adventitia, media
and intima of coronary arteries of male cynomolgus monkeys. Bars
above zero indicate an increase in the number of arteries evaluated
that fell within that lesion grade; bars below zero indicate a decrease
in the number of arteries evaluated that fell within that lesion grade.
*p , 0.05 versus control group.
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Plaque characteristics. The results of our study indicate
that pravastatin has effects on certain characteristics of the
plaque itself that are considered important in the pathogenesis
of plaque disruption. Proliferation of vasa vasorum in the
intima of atherosclerotic lesions is thought to be important in
arterial wall metabolism and nutrition (41,42). These vessels
are, however, thin-walled and fragile and may be prone to
rupture (41). Atherosclerosis augments constrictor responses
of the intimal vasa vasorum (42), which may increase the
chance of intraplaque rupture of vasa, hemorrhage and plaque
rupture. Dietary lowering of plasma cholesterol causes regres-
sion of these intimal vasa in monkeys, possibly by attenuation
of growth factor–stimulated angiogenesis (42). Treatment with
pravastatin resulted in a shift toward less intimal vasa after
dietary lowering of cholesterol. This may serve to stabilize the
plaque by promoting regression of fragile, rupture-prone mi-
crovessels. However, if these vessels are stimulated to regress
too quickly, thickened atherosclerotic arteries may not receive
proper nutrition and may be more prone to necrosis and
rupture. Therefore, one must be cautious about how to inter-
pret regression or involution of plaque vasa vasorum.
Calcification is a frequent feature of complicated athero-
sclerotic plaque. Plaque rupture is commonly seen in associa-
tion with areas of calcification. Why this is so remains uncer-
tain. Calcification may represent fixed hard tissue within an
artery that serves as a mechanical point of plaque disruption or
production of tissue-degrading chemicals. Because we ob-
served less calcification in the arterial intima of pravastatin-
treated monkeys, pravastatin may stabilize atherosclerotic
plaque by inhibiting the formation or promoting the removal of
calcium deposits in atherosclerotic plaque.
Of the cells that are found in atherosclerotic plaque,
macrophages and other inflammatory cells are most often
implicated as being important to plaque disruption (15,16).
Human autopsy studies of the characteristics of sites of fatal
plaque disruption have consistently shown prominent accumu-
lations of macrophages (16). These monocytic cells can exhibit
many functions that alter aspects of atheroma. Macrophages
can degrade extracellular matrix by phagocytosis or by secret-
ing proteolytic enzymes such as plasminogen activators and a
family of metalloproteinases (collagenases, gelatinases and
stromelysins) that may weaken the fibrous cap, predisposing it
to rupture (10). It is thought that accumulations of macro-
phages at the “shoulder” region of the plaque may be espe-
cially dangerous for plaque disruption. In the present study,
there were fewer intimal macrophages in the pravastatin-
treated monkeys than in the untreated control monkeys. In a
separate study, we observed increased proteolytic activity
associated with macrophages found in the intima of athero-
sclerotic arteries (43,44). Thus, a reduction in macrophages by
pravastatin may reduce intraplaque proteolysis and possibly
the risk of plaque rupture.
We did not observe a lipid-independent effect of pravastatin
on other plaque characteristics thought to be important in
plaque disruption. There appeared to be little effect on the
amount of necrosis in the intima or the thickness of the fibrous
cap. Often, plaque disruption is found in areas of the plaque
with extensive amounts of necrosis and associated with a thin,
fibrous cap (12–14). Thus, improvements in necrotic core size
and fibrous cap thickness may have occurred as a result of lipid
lowering, but in this study there appeared to be no further
effect of pravastatin on these plaque characteristics.
Potential study limitations and other considerations.
Throughout this report, we have stated that pravastatin had
(e.g., vascular reactivity) or did not have (e.g., atherosclerosis
extent, fibrous cap thickness) an effect on the experimental end
points. It should be emphasized that many of these end points
(except plasma lipoproteins) were measured at one point in
time (at the beginning or the end of the regression phase). Our
statements hold for these time points but do not address what
may have been happening throughout the regression period or
what might have happened if the regression phase were
extended. In addition, vascular reactivity studies were done
only at the end of the study. We do not know if there were
group differences at the beginning of the treatment phase.
There were no effects of treatment on reduction of lesion size
in the iliac arteries. However, it cannot be determined if the
rate of plaque shrinkage was similar between groups. This may
be important when one attempts to assign significance of
involution of vasa vasorum as a factor in plaque nutrition.
Our evaluation of frequency distributions of plaque char-
acteristics relied on subjective morphologic criteria ill suited
for image analysis. The scores were, however, assigned by two
separate investigators unaware of the other score or which
treatment group was being evaluated. The observed differences
in frequency distribution were consistent and easily discerned.
Several arterial sites were used in this study owing to
limitations on what can be done with the small arteries of
monkeys. Different arterial sites develop atherosclerosis at
distinct rates and presumably regress at different rates. How-
ever, the basic underlying mechanisms of progression and
regression are, most likely, similar. Use of nonhuman primate
tissues in this study had advantages over those of humans
because of the careful control for confounding variables such
as drug treatment, diet, previous operation and cardiovascular
risk factors. In addition, most human studies do not permit
systematic analysis of optimally preserved transmural speci-
mens. They are often difficult to interpret in this regard
because of postmortem changes such as autolysis.
Conclusions. The results of this study indicate that prava-
statin has effects on the artery wall independent of its effects on
plasma lipoprotein concentrations. These include favorable
effects on coronary artery vascular reactivity and a shift away
from plaque characteristics associated with plaque rupture.
Both of these arterial effects may explain, in part, the beneficial
effect of pravastatin on reducing coronary events in humans.
We thank Jamie Fox and Eugenia Schvartz for their technical assistance, and
Diann Weddle, DVM, who did much of the early planning of this experimental
design.
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